3 results

  • signifor

    (pasireotide)
    Recordati Rare Diseases, Inc.
    SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease when pituitary surgery is not a viable option or has not successfully cured the condition.

  • signifor lar

    (pasireotide)
    Recordati Rare Diseases, Inc.
    SIGNIFOR LAR is indicated for treating acromegaly in patients with inadequate surgical response or unsuitable for surgery, and for Cushing's disease when pituitary surgery is not an option or hasn't been curative.

  • somatuline depot

    (lanreotide acetate)
    Ipsen Biopharmaceuticals, Inc.
    SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.